GLP-1 Drugs Cross a New Frontier: From Diabetes to Hearts to Aging

FDA approved Mounjaro (tirzepatide) by Eli Lilly to reduce the risk of major cardiovascular events — heart attacks, strokes, and cardiovascular death — in people with type 2 diabetes at high risk. The SURPASS-CVOT trial showed Mounjaro achieved an 8% lower relative risk of major adverse cardiovascular events (MACE) compared to Trulicity. Heart disease remains the leading killer of diabetics, so this isn't a marginal upgrade — it's a fundamental expansion of what these drugs can...